Harris Erik
EVP & Chief Commercial Officer
Harris Erik has filed 3 SEC Form 4 filings (4 transaction rows) across 2 companies, including RARE, RZLT, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Apr 20, 2026.
On the most recent filing, Harris Erik is listed as EVP & Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. Inside the rolling window, Harris Erik reported no open-market purchases and 1 open-market sale totaling $240K in RARE.
Companies traded
Other insiders at RARE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$240K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Harris Erik made?
Harris Erik has filed 3 SEC Form 4 filings (4 transaction rows) across 2 companies, including RARE, RZLT since 2025.
Which companies does Harris Erik trade?
Harris Erik has filed SEC Form 4 disclosures for 2 companies, including RARE, RZLT.
When was Harris Erik's most recent SEC Form 4 filing?
Harris Erik's most recent SEC Form 4 filing on Tracefour is dated Apr 20, 2026.
What is Harris Erik's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Harris Erik is listed as EVP & Chief Commercial Officer.
What is Harris Erik's total buy and sell value in the current window?
Inside the rolling retention window, Harris Erik bought $0 and sold $240K based on SEC Form 4 filings.
What was Harris Erik's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,539 RARE shares on 2026-03-02, worth $240K, per SEC Form 4 filings.